• Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid

    14 days ago - By San Diego Biotechnology

    Biocept's patented Target Selector technology enables new specimen type-cerebrospinal fluid -to identify biomarkers that can aid physicians in making treatment decisions
    SAN DIEGO, Jan. 14, 2020 /PRNewswire/ - Biocept, Inc. (NASDAQ: B......
    Read more ...